Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,461 total articles
Neurocrine (NBIX) sold off after below-expectation Ingrezza guidance, but the underlying business remains healthy: Ingrezza grew to $2.51B, Q4 sales topped $805.5M, and the company generates meaningful free cash flow. This trade idea buys the weakness with a clear stop and a 180-trading-day target that prices in recovery plus pipeline upside.
Illinois Tool Works (ITW) looks set to outpace the market as automotive and industrial demand normalizes and the company extracts more operating leverage from restructuring and pricing. Valuation is not cheap, but free cash flow generation, a 2%+ dividend, and strong ROE support a disciplined long trade with a clear stop and target.
Sana (SANA) is a speculative long setup that pays to be small and patient. The company’s fusogen in vivo gene-editing work (published in Nature Biotechnology) is a real scientific milestone; the stock is cheap relative to upside if that program wins, but Sana faces cash burn, prior dilution and active litigation. Trade size accordingly and use a ha…
Eos Energy is a high-volatility battery-storage stock that has re-rated on early commercial traction and a large project pipeline. Technicals show the stock pulling back toward support after a big run; the trade targets a breakout to $15 over the next 45 trading days while limiting downside with a $9 stop.
Atlanta Braves Holdings (BATRA) sits at a premium valuation with negative free cash flow and meaningful leverage. Recent options flow and Liberty-related restructuring chatter raise the odds management tests a direct-to-consumer or new local-media approach. If that happens, the company could face higher capex, rights costs, and margin pressure — an…
Norwegian Cruise Line (NCLH) offers a mid-term swing trade setup. Shares are discounted relative to peers, technical momentum is constructive and booking momentum from wave season should flow into revenue and pricing. We lay out an entry at $23.00, stop at $20.00 and a target of $28.00 over a 45 trading-day horizon, with clear triggers that would c…
UniCredit looks like a high-quality European bank whose recent return-on-equity and margin resilience justify paying up relative to peers. With higher-for-longer rates, continued NPL clean-up and management discipline, the stock is a buy for investors willing to hold through macro volatility. This trade idea lays out exact entry, stop and target le…
WEX Inc. looks materially undervalued on cash flow and earnings multiples relative to its growth profile, but recent revenue softness, activist pressure and execution gaps in Mobility and Corporate Payments mean this is a trade, not a buy-and-forget. Enter a measured long at current levels with a firm stop and a target near the 52-week high - a mid…
Targa Resources (TRGP) is priced as a mature midstream owner but is funding a multi-billion dollar Permian buildout that should expand EBITDA and free cash flow over the next 12-18 months. With dividend increases, debt refinancing completed, and a clear pipeline of growth projects, the risk/reward favors loading a position now. This trade outlines …
Amazon has been hit hard in a broad tech selloff driven by AI capex fears. The drop has pushed technical indicators into deeply oversold territory while AWS growth and large-scale AI investment provide a clear fundamental runway. This trade idea lays out an actionable mid-term plan with entry, stop and target, and a balanced view of risks and catal…
Affirm has moved beyond promise to proof: GAAP profitability, accelerating gross merchandise volume, material free cash flow, and strategic partnerships create a clear path for margin expansion. The market's knee-jerk sell-off to $49.86 creates an actionable entry for a long position targeting a re-rating back toward growth multiple peers, with def…
FDA approval of Optune Pax for locally advanced pancreatic cancer materially broadens NovoCure's TAM and gives the stock a near-term re-rating lever. The catalyst is clear; the trade is to buy a measured entry on the post-announcement pullback with defined stop and target.
Arhaus has pulled back to $9.13 after a bout of selling that looks more technical than structural. The business is cash-generative, lightly levered, and expanding showrooms while raising revenue guidance in recent quarters. At roughly $1.29B market cap and a P/S near 1.0, this is a buy-the-dip setup with a clear entry, stop, and target for a mid-te…
Sanofi's board removed CEO Paul Hudson effective 02/17/2026 and named Belén Garijo as incoming CEO on 04/29/2026. The stock has pulled back to $47.03 after the news but trades at a market cap of $113.95B with a P/E of 13.63 and a 3.25% dividend yield. We view the sell-off as an overreaction and recommend a mid-term long with exact entry, stop and t…
Brinker posted crisp operating progress in FY2025: same-store gains at Chili's, restaurant operating margin expansion and >$5B in revenue. Valuation is reasonable (P/E ~16, EV/EBITDA ~10) for a mid-cap casual-dining operator. This is a swing trade idea to buy strength around $162.54, target $175 and protect capital at $156 if traffic momentum stall…
Fairfax Financial (FRFHF) has enjoyed a monster rally, yet core valuation metrics - PE ~7.9 and PB ~1.42 - still argue for more upside. Market cap sits near $40.0B while the company continues to generate substantial earnings and carry a diversified insurance + investment mix. This trade proposes a long with a clear entry, stop and target and balanc…
Microsoft's share price has pulled back with software peers amid macro concern, but the company's durable cloud growth, strong free cash flow ($77.4B), and pristine balance sheet make the current levels attractive. This is a tactical upgrade to BUY with a position-sized plan and clear entry, stop, and target levels for the next 3-6 months.
Boeing has posted improving profitability metrics but still shows negative free cash flow, heavy leverage and stretched multiples. The stock is a tactical long: buy the operational momentum and service-tail gains while protecting against execution and balance-sheet shocks. Entry $239.35, stop $218.00, target $280.00 for a long-term (180 trading day…
Salesforce (CRM) has been chopped down with the rest of SaaS as AI fear and headline risk dominate tape. Fundamentals still show a durable franchise: market cap ~$174B, free cash flow near $12.9B, low net leverage, and P/E ~24. I lay out a long trade with a clear entry, stop and target for a long-term (180 trading days) rebound if the market re-rat…
AOSL is trading at bargain multiples versus sales and book value, but trailing losses and negative free cash flow mean any upside depends on margin recovery and sustained revenue. We outline a mid-term swing trade that balances upside from mean reversion and industry tailwinds against concrete downside protections.
Lululemon trades at a single-digit to mid-teens P/E with healthy cash flow and no net debt, making it historically cheap on fundamentals. Still, leadership uncertainty and continuing U.S. softness argue for a measured, position-sized long with defined stops and a multi-month horizon.
Meta has shifted from near-zero net debt to roughly $60 billion of borrowings over the last five years to fund Reality Labs and AI infrastructure. That change amplifies downside risk despite $46.1B of free cash flow and a $1.67T market cap. We lay out a mid-term short trade that exploits near-term sentiment and valuation pressure while mapping the …
Amazon has the balance sheet, customer base, and AWS scale to develop custom silicon that matters. Short-term price action and oversold technicals create a tactical long opportunity, but execution risk and capital intensity are real. This trade targets a bounce to $230 within ~45 trading days while protecting downside at $188.
Arcturus is trading like a winner despite thin cash runway, negative free cash flow, and elevated short interest. The company has a real European approval for KOSTAIVE, but the market may already be assuming rapid commercial traction and further clinical wins. This trade idea lays out a mid-term short: entry, stop, target, catalysts to watch, and t…
Neurocrine's share drop has created a tactical long opportunity. The stock is oversold after a flurry of mixed clinical updates in late 2025; fundamentals show strong cash generation, no debt, and growing revenue. Price trades at a premium but the balance sheet and franchise support a mid-term rebound. We'll outline a specific entry, stop, and targ…
